Rhythm Pharma amends exec comp; CEO base $717k, severance enhanced for change of control

RHYTHM PHARMACEUTICALS, INC.

CEO Meeker: base salary $717,254, bonus target 65%, severance 12 months (18 months +150% bonus on change in control).
CFO Smith: base $480,000, bonus 40%, severance 9 months (12 months +100% bonus under change in control).
CTO Shulman ($435,000) and EVP Chien ($473,000) receive similar amended terms.
Severance conditioned on release of claims and continued compliance with restrictive covenants.
280G best-pay provision ensures after-tax maximization if excise tax applies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.